Herbst Kinsky has advised Themis Bioscience GmbH on its series B financing round with a volume of approximately EUR 10 Million. Prominent investors in this round are Wellington Partners, Ventech Capital, Omnes Capital, and der aws Grunderfonds.
Themis Bioscience is an international biotech company that develops vaccines against emerging and specialist indications. The fresh capital will be used to complete a phase 2 clinical trial of its lead product, a vaccine candidate against Chikungunya fever.
Erich Tauber, CEO and co-founder of Themis, had this to say about the successful completion of the company’s second financing round: "We are delighted about the continuous trust of our existing investors and of Austria’s leading Venture Fund aws Gruenderfonds. This trust and our recent excellent product development and technology progress have also attracted new investors and we are very grateful for their support."
The Herbst Kinsky team was led by Partner Florian Steinhart and included David Pachernegg and Florian Pollak.
